TSX:IN

Stock Analysis Report

Executive Summary

InMed Pharmaceuticals Inc., a pre-clinical stage biopharmaceutical company, researches and develops cannabinoid-based therapies.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.

Risks

  • InMed Pharmaceuticals has significant price volatility in the past 3 months.
  • InMed Pharmaceuticals is covered by less than 3 analysts.

Share Price & News

How has InMed Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-10.1%

IN

0.6%

CA Biotechs

1.3%

CA Market


1 Year Return

-59.7%

IN

-70.7%

CA Biotechs

-0.1%

CA Market

IN outperformed the Biotechs industry which returned -70.7% over the past year.

IN underperformed the Market in Canada which returned -0.1% over the past year.


Share holder returns

INIndustryMarket
7 Day-10.1%0.6%1.3%
30 Day21.6%6.5%4.7%
90 Day-12.7%-0.8%1.6%
1 Year-59.7%-59.7%-70.7%-70.7%3.4%-0.1%
3 Year195.2%195.2%-29.1%-29.1%19.1%8.4%
5 Yearn/a28.7%28.7%23.2%5.7%

Price Volatility Vs. Market

How volatile is InMed Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is InMed Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

2.93x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for InMed Pharmaceuticals to establish if it is available at moderate discount.

Unable to calculate intrinsic value for InMed Pharmaceuticals to establish if it is available at substantial discount.


Price Based on Earnings

InMed Pharmaceuticals is loss making, we can't compare its value to the North America Biotechs industry average.

InMed Pharmaceuticals is loss making, we can't compare the value of its earnings to the Canada market.


Price Based on Expected Growth

Unable to calculate PEG ratio for InMed Pharmaceuticals, we can't assess if its growth is good value.


Price Based on Value of Assets

InMed Pharmaceuticals is good value based on assets compared to the CA Biotechs industry average.


Next Steps

Future Growth

How is InMed Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

23.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if InMed Pharmaceuticals is high growth as no revenue estimate data is available.

Unable to determine if InMed Pharmaceuticals is high growth as no earnings estimate data is available.

Unable to compare InMed Pharmaceuticals's revenue growth to the Canada market average as no estimate data is available.

Unable to compare InMed Pharmaceuticals's earnings growth to the Canada market average as no estimate data is available.

Unable to compare InMed Pharmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if InMed Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has InMed Pharmaceuticals performed over the past 5 years?

-36.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

InMed Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare InMed Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare InMed Pharmaceuticals's 1-year growth to the North America Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if InMed Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if InMed Pharmaceuticals has efficiently used its assets last year compared to the North America Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if InMed Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is InMed Pharmaceuticals's financial position?


Financial Position Analysis

InMed Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

InMed Pharmaceuticals has no long term commitments.


Debt to Equity History and Analysis

InMed Pharmaceuticals has no debt.

InMed Pharmaceuticals has no debt compared to 5 years ago when it was 0.1%.


Balance Sheet

Low level of unsold assets.

InMed Pharmaceuticals has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

InMed Pharmaceuticals has sufficient cash runway for 2 years based on current free cash flow.

InMed Pharmaceuticals has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 63% each year.


Next Steps

Dividend

What is InMed Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate InMed Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate InMed Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as InMed Pharmaceuticals has not reported any payouts.

Unable to verify if InMed Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as InMed Pharmaceuticals has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of InMed Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Canada.


Next Steps

Management

What is the CEO of InMed Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average management tenure


CEO

Eric Adams (56yo)

3.3yrs

Tenure

CA$2,574,950

Compensation

Mr. Eric A. Adams, B.S. Chem., M.I.B. has been the Chief Executive Officer and President at InMed Pharmaceuticals Inc. since June 16, 2016. Mr. Adams served as a Strategic Advisor of Augurex Life Sciences  ...


CEO Compensation Analysis

Eric's remuneration is higher than average for companies of similar size in Canada.

Eric's compensation has increased whilst company is loss making.


Management Age and Tenure

2.8yrs

Average Tenure

The tenure for the InMed Pharmaceuticals management team is about average.


Board Age and Tenure

1.6yrs

Average Tenure

56yo

Average Age

The average tenure for the InMed Pharmaceuticals board of directors is less than 3 years, this suggests a new board.


Insider Trading

More shares have been bought than sold by InMed Pharmaceuticals individual insiders in the past 3 months.


Recent Insider Transactions

BuyCA$14,74210 Jul 19
Eric Hsu
EntityIndividual
Role
Senior Key Executive
Senior Vice President of Preclinical Research & Development
Shares42,000
Max PriceCA$0.35
BuyCA$6,44004 Jul 19
Michael Woudenberg
EntityIndividual
Role
Other Key Executive
Vice President
Shares17,500
Max PriceCA$0.37
BuyCA$34,78003 Jul 19
Eric Adams
EntityIndividual
Role
Chief Executive Officer
President
Shares100,000
Max PriceCA$0.35
BuyCA$20,06418 Jan 19
Eric Adams
EntityIndividual
Role
Chief Executive Officer
President
Shares40,000
Max PriceCA$0.50
BuyCA$4,91716 Jan 19
Eric Adams
EntityIndividual
Role
Chief Executive Officer
President
Shares10,500
Max PriceCA$0.47
BuyCA$24,18015 Jan 19
Eric Adams
EntityIndividual
Role
Chief Executive Officer
President
Shares50,000
Max PriceCA$0.48

Ownership Breakdown


Management Team

  • Bruce Colwill

    Chief Financial Officer

    • Tenure: 0.08yrs
  • Alexandra D. Mancini

    Senior Vice President of Clinical & Regulatory Affairs

    • Tenure: 2.9yrs
    • Compensation: CA$692.50k
  • Jeff Charpentier

    VP of Finance & Corporate Secretary

    • Tenure: 2.8yrs
    • Compensation: CA$737.65k
  • Paul Brennan

    Strategic Advisor

    • Tenure: 3.3yrs
  • Eric Adams (56yo)

    President

    • Tenure: 3.3yrs
    • Compensation: CA$2.57m
  • Richard Hoy

    Vice President of Sales & Marketing

    • Tenure: 15yrs
  • Eric Hsu

    Senior Vice President of Preclinical Research & Development

    • Tenure: 0.7yrs
    • Compensation: CA$854.58k
  • Sazzad Hossain

    Co-Founder & Member of the Scientific Advisory Board

    • Tenure: 0.7yrs
    • Compensation: CA$184.70k
  • Ado Muhammad

    Senior Consultant of Medical affairs

    • Tenure: 0yrs
  • Michael Woudenberg

    Vice President

    • Tenure: 0.8yrs

Board Members

  • Steven Dinh (63yo)

    Member of Scientific Advisory Board

    • Tenure: 0.5yrs
  • Eric Adams (56yo)

    President

    • Tenure: 3.3yrs
    • Compensation: CA$2.57m
  • Bill Garner (53yo)

    Chairman of the Board

    • Tenure: 0yrs
    • Compensation: CA$21.62k
  • Andy Hull (56yo)

    Director

    • Tenure: 3yrs
    • Compensation: CA$13.31k
  • Adam Cutler (45yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: CA$13.31k
  • Sazzad Hossain

    Co-Founder & Member of the Scientific Advisory Board

    • Tenure: 0.7yrs
    • Compensation: CA$184.70k
  • Catherine Sazdanoff (63yo)

    Director

    • Tenure: 0.2yrs
  • Mauro Maccarrone

    Member of Scientific Advisory Board

    • Tenure: 1.9yrs
  • Vikramaditya Yadav

    Member of Scientific Advisory Board

    • Tenure: 1.3yrs

Company Information

InMed Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: InMed Pharmaceuticals Inc.
  • Ticker: IN
  • Exchange: TSX
  • Founded: 1981
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$53.408m
  • Shares outstanding: 172.28m
  • Website: https://www.inmedpharma.com

Number of Employees


Location

  • InMed Pharmaceuticals Inc.
  • 200 Granville Street
  • Suite 340
  • Vancouver
  • British Columbia
  • V6C 1S4
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
INTSX (The Toronto Stock Exchange)YesCommon SharesCACADAug 1999
MWG2DB (Deutsche Boerse AG)YesCommon SharesDEEURAug 1999
IMLF.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDAug 1999

Biography

InMed Pharmaceuticals Inc., a pre-clinical stage biopharmaceutical company, researches and develops cannabinoid-based therapies. The company’s lead product is INM-750, a topical cannabinoid product candida ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 23:41
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.